Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis

T. R. Mikuls, D. Kahn, P. C. Utrie, S. J. Miller, R. Koehnke, W. Goeckeler, K. G. Saag

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

We examined the preliminary safety and efficacy of intravenous samarium-153-EDTMP (Sm-153) in the treatment of refractory rheumatoid arthritis (RA). In an open-label sequential group comparison of 0.5, 1.0, and 2.0 mCi/kg, Sm-153 was administered as a single intravenous infusion to 24 patients with refractory disease. Across treatment doses, the frequency of American College of Rheumatology (ACR) 20% responses was 25%, 29%, 25%, and 33% at 2, 4, 8, and 12 weeks, respectively. Expected significant declines in absolute neutrophil count, hemoglobin, and platelet counts were observed with nadirs seen between 2-4 weeks. Sm-153, at doses of 0.5 and 1.0mCi/kg, is well tolerated but minimally effective in the treatment of refractory RA as measured using ACR response criteria.

Original languageEnglish (US)
Pages (from-to)356-359
Number of pages4
JournalScandinavian Journal of Rheumatology
Volume30
Issue number6
DOIs
StatePublished - 2001

Keywords

  • Radioisotope
  • Rheumatoid arthritis
  • Samarium-153-EDTMP
  • Treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint Dive into the research topics of 'Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis'. Together they form a unique fingerprint.

  • Cite this

    Mikuls, T. R., Kahn, D., Utrie, P. C., Miller, S. J., Koehnke, R., Goeckeler, W., & Saag, K. G. (2001). Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis. Scandinavian Journal of Rheumatology, 30(6), 356-359. https://doi.org/10.1080/030097401317148561